Stéphanie Desmedt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stéphanie Desmedt has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- David Loose
Department of Otorhinolaryngology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium
2 shared publications - Helen Van Hoecke
Department of Otorhinolaryngology, Ghent University, Ghent, Belgium
2 shared publications - Ingeborg Dhooge
Ghent University
2 shared publications - Thomas Maly
Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
2 shared publications - Arsene-Helene Batens
Ghent University Hospital, Ghent, Belgium
1 shared publication - Bruno Lapauw
Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
1 shared publication
Latest Publications
- 6 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (8) , 2915-2925
The Value of Liquid and Solid Mixed Meal Tolerance Tests in Diagnosis of Postprandial Reactive Hypoglycaemic Syndrome After Gastric Bypass Surgery
Background Precise diagnostics for postprandial reactive hypoglycaemic syndrome (PRHS) after gastric bypass surgery (GBS) are lacking. Oral glucose tolerance tests (OGTT) are advocated but might cause early dumping and lack specificity. This study aims to evaluate glucometabolic responses and symptoms during liquid and solid mixed meal tolerance tests (LMMTT and SMMTT). Methods Twenty-two subjects at least 1 year after GBS, divided into PRHS and non-PRHS based on clinical assessment and 14 control subjects (6 normal-weight, 8 with obesity) participated. All underwent 3-h LMMTT and SMMTT during which glucometabolic responses as well as hypoglycaemic symptoms using the Edinburgh hypoglycaemia symptom scale (EHSS) were assessed. Results During LMMTT, nadir glucose levels nor frequency of levels < 70 mg/dl and < 54 mg/dl did differ between groups. LMMTT could not differentiate between PRHS and non-PRHS in terms of total count of symptoms, and the number of symptoms was not associated with low glycaemia. During SMMTT, glucometabolic responses were similar between PRHS and non-PRHS. However, significantly more hypoglycaemic symptoms were evocated in the group with PRHS compared to those without during the second phase of SMMTT, with more neuroglycopenic and malaise symptoms in the subjects with PRHS. The decrease rate of glucose was higher in subjects with PRHS with malaise symptoms from 105 to 180 min compared to those without malaise. Conclusion LMMTT is not able to differentiate hypoglycaemic symptoms and low glycaemic values between subjects with PRHS and subjects without PRHS, whereas SMMTT could be of greater value. The clinical value of set glucose levels and the use of other biochemical parameters used to diagnose PRHS needs to be further evaluated.
- 6 June 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (8) , 2915-2925
The Value of Liquid and Solid Mixed Meal Tolerance Tests in Diagnosis of Postprandial Reactive Hypoglycaemic Syndrome After Gastric Bypass Surgery
Background Precise diagnostics for postprandial reactive hypoglycaemic syndrome (PRHS) after gastric bypass surgery (GBS) are lacking. Oral glucose tolerance tests (OGTT) are advocated but might cause early dumping and lack specificity. This study aims to evaluate glucometabolic responses and symptoms during liquid and solid mixed meal tolerance tests (LMMTT and SMMTT). Methods Twenty-two subjects at least 1 year after GBS, divided into PRHS and non-PRHS based on clinical assessment and 14 control subjects (6 normal-weight, 8 with obesity) participated. All underwent 3-h LMMTT and SMMTT during which glucometabolic responses as well as hypoglycaemic symptoms using the Edinburgh hypoglycaemia symptom scale (EHSS) were assessed. Results During LMMTT, nadir glucose levels nor frequency of levels < 70 mg/dl and < 54 mg/dl did differ between groups. LMMTT could not differentiate between PRHS and non-PRHS in terms of total count of symptoms, and the number of symptoms was not associated with low glycaemia. During SMMTT, glucometabolic responses were similar between PRHS and non-PRHS. However, significantly more hypoglycaemic symptoms were evocated in the group with PRHS compared to those without during the second phase of SMMTT, with more neuroglycopenic and malaise symptoms in the subjects with PRHS. The decrease rate of glucose was higher in subjects with PRHS with malaise symptoms from 105 to 180 min compared to those without malaise. Conclusion LMMTT is not able to differentiate hypoglycaemic symptoms and low glycaemic values between subjects with PRHS and subjects without PRHS, whereas SMMTT could be of greater value. The clinical value of set glucose levels and the use of other biochemical parameters used to diagnose PRHS needs to be further evaluated.
- Open Access
- 22 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3439
The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.
- 22 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (7) , 3439
Open AccessThe Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases
Patients with chronic kidney disease (CKD) are more prone to oxidative stress and chronic inflammation, which may lead to an increase in the synthesis of advanced glycation end products (AGEs). Because AGEs are mostly removed by healthy kidneys, AGE accumulation is a result of both increased production and decreased kidney clearance. On the other hand, AGEs may potentially hasten decreasing kidney function in CKD patients, and are independently related to all-cause mortality. They are one of the non-traditional risk factors that play a significant role in the underlying processes that lead to excessive cardiovascular disease in CKD patients. When AGEs interact with their cell-bound receptor (RAGE), cell dysfunction is initiated by activating nuclear factor kappa-B (NF-κB), increasing the production and release of inflammatory cytokines. Alterations in the AGE-RAGE system have been related to the development of several chronic kidney diseases. Soluble RAGE (sRAGE) is a decoy receptor that suppresses membrane-bound RAGE activation and AGE-RAGE-related toxicity. sRAGE, and more specifically, the AGE/sRAGE ratio, may be promising tools for predicting the prognosis of kidney diseases. In the present review, we discuss the potential role of AGEs and sRAGE as biomarkers in different kidney pathologies.
- 16 March 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 275 (5) , 1121
Correction to: Long-term hearing results of stapedotomy: analysis of factors affecting outcome
The given and family names of all the co-authors are incorrect in the published article. The correct names should read as follows:
- 16 March 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 275 (5) , 1121
Correction to: Long-term hearing results of stapedotomy: analysis of factors affecting outcome
The given and family names of all the co-authors are incorrect in the published article. The correct names should read as follows:
- 16 February 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 275 (5) , 1111-1119
Long-term hearing results of stapedotomy: analysis of factors affecting outcome
To evaluate long-term hearing results of stapedotomy and analyze the influence of patient-, disease-, and procedure-related variables.
- 16 February 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 275 (5) , 1111-1119
Long-term hearing results of stapedotomy: analysis of factors affecting outcome
To evaluate long-term hearing results of stapedotomy and analyze the influence of patient-, disease-, and procedure-related variables.